DE69739853D1 - Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänen - Google Patents
Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänenInfo
- Publication number
- DE69739853D1 DE69739853D1 DE69739853T DE69739853T DE69739853D1 DE 69739853 D1 DE69739853 D1 DE 69739853D1 DE 69739853 T DE69739853 T DE 69739853T DE 69739853 T DE69739853 T DE 69739853T DE 69739853 D1 DE69739853 D1 DE 69739853D1
- Authority
- DE
- Germany
- Prior art keywords
- immunophilin
- multimizing
- rapamycine
- derivatives
- synthetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000000521 Immunophilins Human genes 0.000 title abstract 4
- 108010016648 Immunophilins Proteins 0.000 title abstract 4
- 239000013543 active substance Substances 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1243296P | 1996-02-28 | 1996-02-28 | |
| US2486196P | 1996-08-28 | 1996-08-28 | |
| US3303596P | 1996-12-10 | 1996-12-10 | |
| PCT/US1997/003137 WO1997031898A1 (en) | 1996-02-28 | 1997-02-28 | Synthetic derivatives of rapamycin as multimerizing agents for chimeric proteins with immunophilin-derived domains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE69739853D1 true DE69739853D1 (de) | 2010-06-02 |
Family
ID=27359637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69739853T Expired - Lifetime DE69739853D1 (de) | 1996-02-28 | 1997-02-28 | Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänen |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0888303B1 (de) |
| JP (2) | JP4936345B2 (de) |
| AT (1) | ATE465149T1 (de) |
| AU (2) | AU731826B2 (de) |
| CA (1) | CA2244363C (de) |
| DE (1) | DE69739853D1 (de) |
| WO (2) | WO1997031899A1 (de) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997031899A1 (en) * | 1996-02-28 | 1997-09-04 | Ariad Gene Therapeutics, Inc. | Synthetic derivatives of rapamycin as multimerising agents for chimeric proteins with immunophilin derived domains |
| US5945441A (en) * | 1997-06-04 | 1999-08-31 | Gpi Nil Holdings, Inc. | Pyrrolidine carboxylate hair revitalizing agents |
| US20010049381A1 (en) | 1997-06-04 | 2001-12-06 | Gpl Nil Holdings, Inc., | Pyrrolidine derivative hair growth compositions and uses |
| US6984635B1 (en) | 1998-02-13 | 2006-01-10 | Board Of Trustees Of The Leland Stanford Jr. University | Dimerizing agents, their production and use |
| AU766513B2 (en) * | 1998-02-13 | 2003-10-16 | Board Of Trustees Of The Leland Stanford Junior University | Novel dimerizing agents, their production and use |
| WO1999050425A2 (en) * | 1998-03-30 | 1999-10-07 | Baylor College Of Medicine | Regulated apoptosis using chemically induced dimerization of apoptosis factors |
| US6331537B1 (en) * | 1998-06-03 | 2001-12-18 | Gpi Nil Holdings, Inc. | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds |
| ZA9811063B (en) * | 1998-06-03 | 2000-07-07 | Guilford Pharm Inc | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds. |
| WO1999062881A1 (en) * | 1998-06-03 | 1999-12-09 | Gpi Nil Holdings, Inc. | Aza-heterocyclic compounds used to treat neurological disorders and hair loss |
| US6300341B1 (en) | 1998-09-30 | 2001-10-09 | The Procter & Gamble Co. | 2-substituted heterocyclic sulfonamides |
| US6307049B1 (en) | 1998-09-30 | 2001-10-23 | The Procter & Gamble Co. | Heterocyclic 2-substituted ketoamides |
| US6566073B1 (en) | 1998-10-19 | 2003-05-20 | Ariad Gene Therapeutics, Inc. | Materials and methods involving conditional retention domains |
| AU3770800A (en) | 1999-03-26 | 2000-10-16 | Amgen, Inc. | Beta secretase genes and polypeptides |
| CA2379149A1 (en) | 1999-07-09 | 2001-01-18 | Ortho-Mcneil Pharmaceutical, Inc. | Neurotrophic pyrrolidines and piperidines, and related compositions and methods |
| AU6388500A (en) * | 1999-08-05 | 2001-03-05 | Procter & Gamble Company, The | Multivalent sulfonamides |
| WO2001010838A1 (en) * | 1999-08-05 | 2001-02-15 | The Procter & Gamble Company | Multivalent compounds |
| WO2001010836A1 (en) * | 1999-08-05 | 2001-02-15 | The Procter & Gamble Company | Method of treating hair loss using multivalent ketoamides and amides |
| US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| US7408047B1 (en) | 1999-09-07 | 2008-08-05 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| US6900043B1 (en) | 1999-09-21 | 2005-05-31 | Amgen Inc. | Phosphatases which activate map kinase pathways |
| EP1125925A1 (de) * | 2000-02-15 | 2001-08-22 | Applied Research Systems ARS Holding N.V. | Amin-Derivate zur Behandlung von Apoptosis |
| AR030554A1 (es) | 2000-03-16 | 2003-08-27 | Amgen Inc | Moleculas similares a receptores il-17 y usos de las mismas |
| US7514239B2 (en) | 2000-03-28 | 2009-04-07 | Amgen Inc. | Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof |
| EP1294879B1 (de) | 2000-06-28 | 2008-12-31 | Amgen Inc. | Thymus-stroma lymphopoietin rezeptor-moleküle und deren verwendung |
| US7662924B2 (en) | 2002-02-22 | 2010-02-16 | The Board Of Trustees Of The University Of Illinois | Beta chain-associated regulator of apoptosis |
| ES2249986B1 (es) * | 2004-07-02 | 2007-02-01 | Universidad Complutense De Madrid | Sintesis de derivados fluorescentes de tacrolimus (fk506) y su uso en la caracterizacion de la interaccion de fk506 con proteinas de union a fk506. |
| US7629315B2 (en) | 2005-03-09 | 2009-12-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Compositions for blocking the inhibitory effect of human CRP on human leptin |
| JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
| JP5878757B2 (ja) | 2008-10-10 | 2016-03-08 | アムジエン・インコーポレーテツド | Ｆｇｆ２１変異体およびその使用 |
| NZ596037A (en) | 2009-05-05 | 2013-10-25 | Amgen Inc | Fgf21 mutants and uses thereof |
| EP2427207B1 (de) | 2009-05-05 | 2017-08-16 | Amgen, Inc | Fgf21-mutanten und ihre verwendungen |
| UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
| WO2011126808A2 (en) | 2010-03-29 | 2011-10-13 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
| US9315825B2 (en) | 2010-03-29 | 2016-04-19 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
| US9517264B2 (en) | 2010-04-15 | 2016-12-13 | Amgen Inc. | Human FGF receptor and β-Klotho binding proteins |
| EP2699688A1 (de) | 2011-04-20 | 2014-02-26 | The Trustees Of The University Of Pennsylvania | Dosierpläne und zusammensetzungen zur aav-vermittelten passiven immunisierung von luftbürtigen krankheitserregern |
| WO2013186264A1 (en) | 2012-06-12 | 2013-12-19 | Universitätsspital Basel | Immortalized mesenchymal stem cells that can be killed through an inducible apoptosis system |
| WO2015012924A2 (en) | 2013-04-29 | 2015-01-29 | The Trustees Of The University Of Pennsylvania | Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof |
| CN103242218B (zh) * | 2013-05-24 | 2015-04-15 | 深圳市天和医药科技开发有限公司 | N-取代哌可酸衍生物及其制备方法与应用 |
| PL3888674T3 (pl) | 2014-04-07 | 2024-09-23 | Novartis Ag | Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19 |
| CN114107424A (zh) | 2014-10-08 | 2022-03-01 | 诺华股份有限公司 | 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途 |
| CA3197849A1 (en) | 2014-12-29 | 2016-07-07 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| PL3280729T3 (pl) | 2015-04-08 | 2022-08-22 | Novartis Ag | Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19 |
| JP7114457B2 (ja) | 2015-04-17 | 2022-08-08 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | キメラ抗原受容体発現細胞の有効性および増殖を改善するための方法 |
| US11535665B2 (en) | 2015-05-13 | 2022-12-27 | The Trustees Of The University Of Pennsylvania | AAV-mediated expression of anti-influenza antibodies and methods of use thereof |
| CN109476722A (zh) | 2015-07-21 | 2019-03-15 | 诺华股份有限公司 | 用于改善免疫细胞的功效和扩张的方法 |
| CN116334205A (zh) | 2015-09-03 | 2023-06-27 | 诺华股份有限公司 | 预测细胞因子释放综合征的生物标志物 |
| US20180230489A1 (en) | 2015-10-28 | 2018-08-16 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
| SG11201805449PA (en) | 2015-12-28 | 2018-07-30 | Novartis Ag | Methods of making chimeric antigen receptor -expressing cells |
| EP3464375A2 (de) | 2016-06-02 | 2019-04-10 | Novartis AG | Therapeutische schemata für chimäre antigenrezeptor(car)-exprimierende zellen |
| AU2017341047B2 (en) | 2016-10-07 | 2024-10-10 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
| CN110121559A (zh) | 2016-11-21 | 2019-08-13 | 特里比奥迪卡有限责任公司 | 通过模板化组装反应进行蛋白质的定向折叠组装或二聚化的方法 |
| WO2018094070A1 (en) | 2016-11-21 | 2018-05-24 | Tribiotica Llc | Methods for preventing titration of bimolecular templated assembly reactions by structurally-determined differential hybridizations |
| AU2018229293A1 (en) | 2017-02-28 | 2019-08-29 | Janssen Biotech, Inc. | Influenza vaccines based on AAV vectors |
| HUE065885T2 (hu) | 2017-02-28 | 2024-06-28 | Univ Pennsylvania | Adeno-asszociált vírus (AAV) F klád vektor és alkalmazásai |
| JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
| EP3624811A4 (de) | 2017-05-19 | 2021-03-10 | The Regents of The University of California | Antikörperbasierter chemisch induzierter dimerisierer (abcid) als molekulare schalter zur regulierung von zelltherapien |
| EP3700926A1 (de) | 2017-10-25 | 2020-09-02 | Novartis AG | Verfahren zur herstellung von chimären antigenrezeptor-exprimierenden zellen |
| EP3788369A1 (de) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarker zur auswertung von car-t-zellen zur vorhersage des klinischen ergebnisses |
| US20210213063A1 (en) | 2018-05-25 | 2021-07-15 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| WO2019237035A1 (en) | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| EP3844267A2 (de) | 2018-08-31 | 2021-07-07 | Novartis AG | Verfahren zur herstellung von zellen zur expression des chimären antigenrezeptors |
| US20210171909A1 (en) | 2018-08-31 | 2021-06-10 | Novartis Ag | Methods of making chimeric antigen receptor?expressing cells |
| EP3856782A1 (de) | 2018-09-28 | 2021-08-04 | Novartis AG | Chimärer cd19-antigen-rezeptor (car) und cd22-car-kombinationstherapien |
| WO2020069405A1 (en) | 2018-09-28 | 2020-04-02 | Novartis Ag | Cd22 chimeric antigen receptor (car) therapies |
| CN109734655B (zh) * | 2019-03-11 | 2020-06-02 | 都创(上海)医药科技有限公司 | 一种fkbp配体的同型二聚体合成工艺 |
| EP3953455A1 (de) | 2019-04-12 | 2022-02-16 | Novartis AG | Verfahren zur herstellung von zellen zur expression des chimären antigenrezeptors |
| US20230111593A1 (en) | 2020-02-14 | 2023-04-13 | Novartis Ag | Method of predicting response to chimeric antigen receptor therapy |
| WO2021173985A2 (en) | 2020-02-27 | 2021-09-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| AU2021378316A1 (en) | 2020-11-13 | 2023-06-01 | Novartis Ag | Combination therapies with chimeric antigen receptor (car)-expressing cells |
| WO2022119871A2 (en) | 2020-12-01 | 2022-06-09 | The Trustees Of The University Of Pennsylvania | Novel compositions with tissue-specific targeting motifs and compositions containing same |
| US20240207452A1 (en) | 2021-04-23 | 2024-06-27 | The Trustees Of The University Of Pennsylvania | Novel compositions with brain-specific targeting motifs and compositions containing same |
| WO2023056399A1 (en) | 2021-10-02 | 2023-04-06 | The Trustees Of The University Of Pennsylvania | Novel aav capsids and compositions containing same |
| JP2025504910A (ja) | 2022-01-25 | 2025-02-19 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 心臓形質導入の改善及び肝臓の脱標的化のためのａａｖカプシド |
| WO2024056809A1 (en) | 2022-09-15 | 2024-03-21 | Novartis Ag | Treatment of autoimmune disorders using chimeric antigen receptor therapy |
| WO2024130070A2 (en) | 2022-12-17 | 2024-06-20 | The Trustees Of The University Of Pennsylvania | Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof |
| WO2024130067A2 (en) | 2022-12-17 | 2024-06-20 | The Trustees Of The University Of Pennsylvania | Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same |
| WO2025007046A1 (en) | 2023-06-29 | 2025-01-02 | The Trustees Of The University Of Pennsylvania | Mutant aav with central nervous system targeting motifs and compositions containing same |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5120727A (en) * | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Rapamycin dimers |
| US5162333A (en) * | 1991-09-11 | 1992-11-10 | American Home Products Corporation | Aminodiesters of rapamycin |
| EP0804561B1 (de) * | 1993-02-12 | 2009-12-30 | The Board Of Trustees Of The Leland Stanford Junior University | Regulierte transkription von zielgerichteten genen und andere biologische ereignisse |
| US5798355A (en) * | 1995-06-07 | 1998-08-25 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity |
| EP0776327B1 (de) * | 1994-08-18 | 2005-07-06 | Ariad Gene Therapeutics, Inc. | Neues multimerisierendes reagenz |
| WO1997031899A1 (en) * | 1996-02-28 | 1997-09-04 | Ariad Gene Therapeutics, Inc. | Synthetic derivatives of rapamycin as multimerising agents for chimeric proteins with immunophilin derived domains |
-
1997
- 1997-02-28 WO PCT/US1997/003157 patent/WO1997031899A1/en active Application Filing
- 1997-02-28 AT AT97907937T patent/ATE465149T1/de not_active IP Right Cessation
- 1997-02-28 CA CA002244363A patent/CA2244363C/en not_active Expired - Lifetime
- 1997-02-28 AU AU19809/97A patent/AU731826B2/en not_active Expired
- 1997-02-28 DE DE69739853T patent/DE69739853D1/de not_active Expired - Lifetime
- 1997-02-28 JP JP53113997A patent/JP4936345B2/ja not_active Expired - Lifetime
- 1997-02-28 WO PCT/US1997/003137 patent/WO1997031898A1/en active Application Filing
- 1997-02-28 EP EP97907937A patent/EP0888303B1/de not_active Expired - Lifetime
- 1997-02-28 AU AU21927/97A patent/AU2192797A/en not_active Abandoned
-
2012
- 2012-01-10 JP JP2012002326A patent/JP2012131794A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP4936345B2 (ja) | 2012-05-23 |
| AU1980997A (en) | 1997-09-16 |
| CA2244363A1 (en) | 1997-09-04 |
| CA2244363C (en) | 2006-11-14 |
| EP0888303B1 (de) | 2010-04-21 |
| WO1997031899A1 (en) | 1997-09-04 |
| EP0888303A1 (de) | 1999-01-07 |
| AU731826B2 (en) | 2001-04-05 |
| AU2192797A (en) | 1997-09-16 |
| JP2012131794A (ja) | 2012-07-12 |
| WO1997031898A1 (en) | 1997-09-04 |
| JP2000505475A (ja) | 2000-05-09 |
| ATE465149T1 (de) | 2010-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69739853D1 (de) | Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänen | |
| AU3367995A (en) | New multimerizing agents | |
| ATE218859T1 (de) | Liganden des neuropeptids y | |
| DE68925155D1 (de) | Verwendung von Halogenkohlenwasserstofflösungsmittel als Reinigungsmittel | |
| TR200800474T2 (tr) | Florfenikole aracı maddelerin hazırlanmasına ilişkin işlem. | |
| BG103485A (en) | Ketobanzamides as calpain inhibitors | |
| DK0778277T3 (da) | Substituerede heterocycliske derivater som CRF antagonister | |
| ATE215530T1 (de) | 7-substituierte-8-substituierte-9-substituierte amino-7-demethyl-6-deoxy-tetracycline als antibiotische mittel | |
| ATE156838T1 (de) | Neue 7-beta-substituierte-4-aza-5-alpha-androstan-3- nen als inhibitoren 5-alpha-reduktases | |
| BR9808491A (pt) | Compostos calcilìticos | |
| EP1134214A4 (de) | Picolinamid-derivate und diese als aktiven bestandteil enthaltende pestizide | |
| WO1997025321A3 (en) | Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin | |
| AP9701007A0 (en) | Substituted azetidin-2-ones for treatment of atherosclerosis. | |
| BG103310A (en) | Benzonaphthyridins as bronchial therapeutical means | |
| NO944406D0 (no) | Nye 7 se inhibitorer | |
| DE69413167D1 (de) | Peptid-Phosphinyloxymethyl-Ketonen als Inhibitoren von Interleukin-1 beta-konvertierenden Enzymen | |
| PL341239A1 (en) | Dihydrobenzofuranes | |
| BR9607335A (pt) | Compostos 1-aril-2-acrilamino-etano e seu uso como neuroquinina especialmente antogonistas de neuroquinina 1 | |
| ES2104174T3 (es) | Derivados de bencilamino, bencilamido y bencilimido ciclicos utilizados como agentes antipsicoticos. | |
| ATE167664T1 (de) | Verwendung von aminen in ölzusammensetzungen | |
| AU3577295A (en) | Reagent for the determination of free radicals | |
| AU3350195A (en) | Bicyclic carboxamides as 5-HT-1A antagonists | |
| DE69606776D1 (en) | Synthese von carbonsäurederivaten | |
| NO305556B1 (no) | Tiokarbamoylforbindelser og anvendelse derav samt middel for beskyttelse av tekniske materialer | |
| AU1121892A (en) | Isoquinoline derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |